Legendre P, Chahwan D, Marjanovic Z, et al. - Researchers performed a retrospective multicenter cohort investigation among patients taking Immunoglobulin replacement therapy (IgRT) for secondary immune deficiency (SID) during 2012. From the first dose of Ig delivered in 2012 to 1 year afterward, data were retrospectively gathered, in terms of the indication for IgRT, and efficacy and safety. This study involved 16 hospitals and 368 patients. Non-Hodgkin lymphoma (82 [22.3%] patients), multiple myeloma (76 [20.7%]), chronic lymphocytic leukemia (64 [17.4%]) and other (79 [21.5%]) were reported as the indications for IgRT. According to the findings, 2011 European Medical Agency recommendations were met by only 24.2% of patients with SID who took IgRT, this was true whatever the criteria, and this is indicative of a misuse of IgRT in SID.